Published in Pediatrics on May 01, 2006
Language impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr (2012) 1.08
Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol (2008) 0.99
Long-term outcomes of pneumococcal meningitis in childhood and adolescence. Eur J Pediatr (2011) 0.87
Could hearing loss be related to delay in administration of other antibiotics rather than early use of vancomycin? Pediatrics (2007) 0.75
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med (2015) 6.04
Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe (2007) 5.46
Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med (2015) 4.90
Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J (2004) 2.53
Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis (2005) 2.43
Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis (2010) 2.01
Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol (2006) 2.01
Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med (2007) 1.99
Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis (2009) 1.93
N-linked glycosylation attenuates H3N2 influenza viruses. J Virol (2007) 1.92
PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog (2010) 1.75
The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis. J Virol (2010) 1.63
Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to superinfection with Gram-positive respiratory pathogens. J Virol (2012) 1.57
Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis (2011) 1.56
Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine (2008) 1.54
T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med (2012) 1.53
The judicious use of antibiotics--an investment towards optimized health care. Indian J Pediatr (2006) 1.52
Bacterial sinusitis and otitis media following influenza virus infection in ferrets. Infect Immun (2006) 1.51
Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics (2008) 1.49
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis (2011) 1.49
Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria. J Immunol (2007) 1.40
Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine (2004) 1.36
Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol (2013) 1.34
MKP-1 switches arginine metabolism from nitric oxide synthase to arginase following endotoxin challenge. Am J Physiol Cell Physiol (2007) 1.28
Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 1.26
Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol (2009) 1.20
Motivating factors for high rates of influenza vaccination among healthcare workers. Vaccine (2011) 1.18
Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog (2013) 1.16
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine (2009) 1.15
Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis (2011) 1.12
Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med (2010) 1.09
Immunopathogenic and antibacterial effects of H3N2 influenza A virus PB1-F2 map to amino acid residues 62, 75, 79, and 82. J Virol (2011) 1.09
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother (2005) 1.07
Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am J Respir Cell Mol Biol (2005) 1.06
Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis (2006) 1.06
Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer (2005) 1.04
Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol (2011) 1.03
Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol (2011) 1.02
Implementation of and barriers to routine HIV screening for adolescents. Pediatrics (2009) 1.01
Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis (2012) 1.01
Planning for an influenza pandemic: thinking beyond the virus. J Infect Dis (2008) 1.01
Role of bacterial DNA in macrophage activation by group B streptococci. Microbes Infect (2008) 0.99
Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol (2008) 0.99
Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant mice. J Virol (2011) 0.99
Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis (2011) 0.99
Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol (2010) 0.98
WASP- mice exhibit defective immune responses to influenza A virus, Streptococcus pneumoniae, and Mycobacterium bovis BCG. Exp Hematol (2005) 0.98
Gene expression profiling of the response of Streptococcus pneumoniae to penicillin. J Antimicrob Chemother (2007) 0.98
Role of vav1- and src-related tyrosine kinases in macrophage activation by CpG DNA. J Biol Chem (2004) 0.97
Live attenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice. J Infect Dis (2013) 0.97
Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J (2010) 0.95
c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine (2008) 0.93
SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages. Biochem Biophys Res Commun (2006) 0.93
Immunotherapy with a combination of intravenous immune globulin and p4 peptide rescues mice from postinfluenza pneumococcal pneumonia. Antimicrob Agents Chemother (2011) 0.92
Group B streptococci exposed to rifampin or clindamycin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr Res (2005) 0.91
FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther (2008) 0.91
Use of atmospheric non-thermal plasma as a disinfectant for objects contaminated with methicillin-resistant Staphylococcus aureus. Am J Infect Control (2009) 0.90
Cytokine-induced arginase activity in pulmonary endothelial cells is dependent on Src family tyrosine kinase activity. Am J Physiol Lung Cell Mol Physiol (2008) 0.89
A novel cytotoxic sequence contributes to influenza A viral protein PB1-F2 pathogenicity and predisposition to secondary bacterial infection. J Virol (2013) 0.88
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother (2007) 0.87
Role of bacterial components in macrophage activation by the LAC and MW2 strains of community-associated, methicillin-resistant Staphylococcus aureus. Cell Immunol (2011) 0.87
Secondary bacterial infections in influenza virus infection pathogenesis. Curr Top Microbiol Immunol (2014) 0.86
Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses (2009) 0.86
Therapeutics against influenza. Curr Top Microbiol Immunol (2013) 0.86
A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO Mol Med (2014) 0.86
Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis (2013) 0.85
Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine (2011) 0.84
The age distribution of mortality due to influenza: pandemic and peri-pandemic. BMC Med (2012) 0.83
Molecular signatures of virulence in the PB1-F2 proteins of H5N1 influenza viruses. Virus Res (2013) 0.82
Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine (2011) 0.82
Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J (2013) 0.82
A single point mutation (Y89F) within the non-structural protein 1 of influenza A viruses limits epithelial cell tropism and virulence in mice. Am J Pathol (2012) 0.82
Ketamine inhibits tumor necrosis factor secretion by RAW264.7 murine macrophages stimulated with antibiotic-exposed strains of community-associated, methicillin-resistant Staphylococcus aureus. BMC Immunol (2011) 0.81
Role of vav1 in the lipopolysaccharide-mediated upregulation of inducible nitric oxide synthase production and nuclear factor for interleukin-6 expression activity in murine macrophages. Clin Diagn Lab Immunol (2004) 0.81
Vaccines against pandemic influenza: what can be done before the next pandemic? Pediatr Infect Dis J (2008) 0.81
Gastroenteritis caused by Edwardsiella tarda in a pediatric renal transplant recipient. Pediatr Transplant (2007) 0.81
Acute necrotizing ulcerative gingivitis and bacteremia caused by Stenotrophomonas maltophilia in an immunocompromised host. Pediatr Infect Dis J (2005) 0.80
New virulence determinants contribute to the enhanced immune response and reduced virulence of an influenza A virus A/PR8/34 variant. J Infect Dis (2013) 0.80
Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages. Int J Inflam (2012) 0.79
Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol (2011) 0.79
Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein. Glycobiology (2011) 0.79
Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother (2013) 0.78
Discordant rise in galactomannan antigenemia in a patient with resolving Aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol (2005) 0.78
Risk of catheter-associated infection in young hematology/oncology patients receiving long-term peripheral nerve blocks. Paediatr Anaesth (2012) 0.78
The clinical need for new antiviral drugs directed against influenza virus. J Infect Dis (2006) 0.78
Levels of total fungus and Aspergillus on a pediatric hematopoietic stem cell transplant unit. J Pediatr Oncol Nurs (2004) 0.77
Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer (2013) 0.77
Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant (2014) 0.77
Manifestations of fungal cellulitis of the orbit in children with neutropenia and fever. Ophthal Plast Reconstr Surg (2004) 0.76
A practical guide to alcohol-based hand hygiene infrastructure in a resource-poor pediatric hospital. Am J Infect Control (2009) 0.76
No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies. Influenza Other Respir Viruses (2011) 0.76
Are toilet seats a vector for transmission of methicillin-resistant Staphylococcus aureus? Am J Infect Control (2009) 0.76
Pneumonitis associated with Ureaplasma urealyticum in children with cancer. Clin Infect Dis (2002) 0.76
Advances in vaccine technology and their impact on managed care. P T (2008) 0.75